A drug initially developed for ulcerative colitis has shown promise as an itch-reducing, quality of life-improving treatment for atopic dermatitis, according to research presented by Professor Dedee Murrell at the International Congress of Dermatology 2021. The sphingosine 1-phosphate (S1P) receptor modulator, etrasimod, recently underwent a phase II clinical trial, with 140 moderate-to-severe atopic dermatitis patients taking ...
ICD 2021: Novel drug shows promise in atopic dermatitis, says Professor Dedee Murrell
By Natasha Doyle
17 Nov 2021